Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Citius Pharmaceuticals, Inc. (CTXR)
USD0.53
0.00 (-0.17%)
US NASDAQ Healthcare Biotechnology
Address
11 Commerce Drive 7016
Cranford, NJ, US
Cranford, NJ, US
CEO
Leonard L. Mazur
Website
citiuspharma.com
IPO
2014-10-02
CIK 1506251 ISIN US17322U3068
Also trades on
NASDAQ Capital Market · CTXR (USD)
NASDAQ Capital Market · CTXRW (USD)
Description
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.53
0.00 (-0.17%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
631.7K
Beta
0.98
Float Shares
10.53M
Free Float %
94.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.72% | +8.86% | -18.40% | -5.54% | -25.10% | -9.86% | -9.04% | -97.45% | -98.58% | -99.86% | -99.81% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
0.53
DCF (Unlevered)
0.93
+74.2%
DCF (Levered)
0.22
-58.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-4.38
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+43.4% ★ Q1'26: +25.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%— Q1'26: -78.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%— Q1'26: -1,931.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-51.2% Q1'26: -195.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-4.5% ★ Q1'26: +93.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.05× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Sep 2022 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 1 Rev. Ana. 1 EPS Ana. |
Sep 2027 1 Rev. Ana. 1 EPS Ana. |
Sep 2028 1 Rev. Ana. 1 EPS Ana. |
Sep 2029 1 Rev. Ana. 1 EPS Ana. |
Sep 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 103.16M (-100.0%)
|
—
est: 61.72M (-100.0%)
|
—
est: 7.67M (-100.0%)
|
78.29M
78.29M – 78.29M
+920.1% YoY
|
143.76M
143.76M – 143.76M
+83.6% YoY
|
183.68M
183.68M – 183.68M
+27.8% YoY
|
208.53M
208.53M – 208.53M
+13.5% YoY
|
221.36M
221.36M – 221.36M
+6.2% YoY
|
| EBITDA |
-32.88M
|
-38.64M
|
-38.20M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-33.06M
|
-38.85M
|
-38.42M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-33.64M
est: -62.30M (+46.0%)
|
-39.14M
est: -63.29M (+38.2%)
|
-37.43M
est: -32.81M (-14.1%)
|
18.37M
18.37M – 18.37M
+156.0% YoY
|
30.87M
30.87M – 30.87M
+68.1% YoY
|
27.44M
27.44M – 27.44M
-11.1% YoY
|
31.31M
31.31M – 31.31M
+14.1% YoY
|
32.75M
32.75M – 32.75M
+4.6% YoY
|
| SGA |
15.66M
|
18.25M
|
18.53M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-5.76
est: -5.38 (-7.2%)
|
-5.97
est: -5.72 (-4.4%)
|
-3.38
est: -2.97 (-14.0%)
|
1.66
1.66 – 1.66
+156.0% YoY
|
2.79
2.79 – 2.79
+68.1% YoY
|
2.48
2.48 – 2.48
-11.1% YoY
|
2.83
2.83 – 2.83
+14.1% YoY
|
2.96
2.96 – 2.96
+4.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
20
Total invested
387.3K
Insider transactions (90d)
0
Beneficial owners (>5%)
13
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Citius Pharmaceuticals, Inc. | 66.05M | 92.60% | 66.05M | — | 66.05M | — | CO | — | 2024-08-16 | ↗ |
| 2 | Leonard L. Mazur | 11.07M | 54.20% | 11.07M | — | 11.07M | — | IN | United States | 2018-08-27 | ↗ |
| 3 | (1)Names of reporting persons. BlackRock, Inc. | 8.46M | 5.30% | 8.33M | — | 8.46M | — | HC | Delaware | 2024-01-31 | ↗ |
| 4 | Armistice Capital, LLC | 2.43M | 1.60% | — | 2.43M | — | 2.43M | IA, OO | — | 2022-02-15 | ↗ |
| 5 | Steven Boyd | 2.43M | 1.60% | — | 2.43M | — | 2.43M | HC, IN | — | 2022-02-15 | ↗ |
| 6 | (1) BlackRock, Inc. | 2.35M | 1.60% | 2.35M | — | 2.35M | — | HC | Delaware | 2022-07-08 | ↗ |
| 7 | Myron Z. Holubiak | 2.15M | 12.60% | 2.15M | — | 2.15M | — | IN | United States | 2018-08-27 | ↗ |
| 8 | Armistice Capital Master Fund Ltd. | 1.89M | 9.99% | — | 1.89M | — | 1.89M | CO | Delaware | 2019-02-14 | ↗ |
| 9 | Craig A. Drill | 693.6K | 2.40% | — | 693.6K | — | 693.6K | HC, IN | United States of America | 2020-02-06 | ↗ |
| 10 | Craig Drill Capital Corporation | 693.6K | 2.40% | — | 693.6K | — | 693.6K | IA, CO | United States of America | 2020-02-06 | ↗ |
| 11 | Craig Drill Capital, L.L.C. | 693.6K | 2.40% | — | 693.6K | — | 693.6K | OO | United States of America | 2020-02-06 | ↗ |
| 12 | Craig Drill Capital, L.P. | 521.7K | 6.09% | — | 521.7K | — | 521.7K | PN | United States of America | 2018-01-26 | ↗ |
| 13 | Craig Drill Capital II, L.P. | 229.3K | 2.70% | — | 229.3K | — | 229.3K | PN | United States of America | 2018-01-26 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
20
-21 vs prev Q
New positions
7
Closed positions
27
Increased
10
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | HEIGHTS CAPITAL MANAGEMENT, INC | 799.9K +799.9K (+100.0%) | 621.5K +621.5K (+100.0%) | 3.72% +3.721 pp | 0.22% +0.223 pp | USD0.78 +0.0% | 3 qtrs — |
| 2 | VANGUARD GROUP INC | 199.3K +32.9K (+19.8%) | 154.8K -51.5K (-25.0%) | 0.93% -0.585 pp | 0.00% +0.000 pp | USD2.27 -65.6% | 5 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 127.5K +7.8K (+6.5%) | 99.1K -49.4K (-33.3%) | 0.59% -0.495 pp | 0.00% +0.000 pp | USD2.64 -70.5% | 5 qtrs — |
| 4 | XTX TOPCO LTD | 107.1K +91.2K (+572.8%) | 83.2K +63.5K (+321.6%) | 0.50% +0.354 pp | 0.00% +0.001 pp | USD0.90 -13.3% | 3 qtrs — |
| 5 | UBS GROUP AG | 76.4K +50.5K (+195.0%) | 59.4K +27.3K (+84.8%) | 0.36% +0.120 pp | 0.00% +0.000 pp | USD1.16 -32.8% | 5 qtrs — |
| 6 | BLACKROCK, INC. | 69.9K +— (+0.0%) | 54.3K -32.3K (-37.3%) | 0.33% -0.310 pp | 0.00% +0.000 pp | USD4.00 -80.5% | 5 qtrs — |
| 7 | CITADEL ADVISORS LLC | 67.1K -25.2K (-27.3%) | 52.1K -62.3K (-54.4%) | 0.31% -0.526 pp | 0.00% +0.000 pp | USD1.55 -49.7% | 5 qtrs — |
| 8 | TWO SIGMA INVESTMENTS, LP | 60.8K +39.0K (+179.0%) | 47.3K +20.2K (+74.8%) | 0.28% +0.085 pp | 0.00% +0.000 pp | USD1.02 -23.5% | 3 qtrs — |
| 9 | — | 59.0K +59.0K (+100.0%) | 45.9K +45.9K (+100.0%) | 0.53% +0.533 pp | 0.02% +0.023 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 10 | NORTHERN TRUST CORP | 44.0K +16.9K (+62.7%) | 34.2K +657.0 (+2.0%) | 0.20% -0.041 pp | 0.00% +0.000 pp | USD1.83 -57.4% | 5 qtrs — |
| 11 | TWO SIGMA SECURITIES, LLC | 28.6K +28.6K (+100.0%) | 22.2K +22.2K (+100.0%) | 0.13% +0.133 pp | 0.00% +0.003 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 12 | LPL FINANCIAL LLC | 25.1K +25.1K (+100.0%) | 19.5K +19.5K (+100.0%) | 0.23% +0.227 pp | 0.00% +0.000 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 13 | STATE STREET CORP | 23.3K +— (+0.0%) | 18.1K -10.8K (-37.3%) | 0.11% -0.103 pp | 0.00% +0.000 pp | USD4.00 -80.5% | 5 qtrs — |
| 14 | SCIENTECH RESEARCH LLC | 20.9K +20.9K (+100.0%) | 16.2K +16.2K (+100.0%) | 0.10% +0.097 pp | 0.01% +0.010 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 15 | ARKADIOS WEALTH ADVISORS | 20.0K +— (+0.0%) | 15.5K -9.3K (-37.3%) | 0.09% -0.089 pp | 0.00% 0.000 pp | USD2.80 -72.1% | 5 qtrs — |
| 16 | JANE STREET GROUP, LLC | 18.0K -927.0 (-4.9%) | 14.0K -9.5K (-40.4%) | 0.08% -0.088 pp | 0.00% +0.000 pp | USD1.24 -37.1% | 2 qtrs — |
| 17 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 12.9K -35.3K (-73.2%) | 10.0K -49.7K (-83.2%) | 0.06% -0.378 pp | 0.00% +0.000 pp | USD1.34 -41.8% | 3 qtrs — |
| 18 | IFP ADVISORS, INC | 7.1K +— (+0.0%) | 5.5K -3.3K (-37.3%) | 0.03% -0.031 pp | 0.00% 0.000 pp | USD4.00 -80.5% | 5 qtrs — |
| 19 | CHELSEA COUNSEL CO | 4.6K +— (+0.0%) | 3.6K -2.1K (-37.3%) | 0.02% -0.021 pp | 0.00% -0.001 pp | USD1.49 -47.7% | 4 qtrs — |
| 20 | SBI SECURITIES CO., LTD. | 4.0K -2.0 (0.0%) | 3.1K -1.9K (-37.4%) | 0.02% -0.018 pp | 0.00% +0.000 pp | USD2.95 -73.6% | 5 qtrs — |
| 21 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.8K +2.8K (+100.0%) | 2.2K +2.2K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 22 | CURIO WEALTH, LLC | 2.0K +2.0K (+100.0%) | 1.6K +1.6K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.001 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 23 | MORGAN STANLEY | 2.0K +1.6K (+399.3%) | 1.6K +1.1K (+213.1%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD0.95 -17.9% | 5 qtrs — |
| 24 | ADVISOR GROUP HOLDINGS, INC. | 1.5K +— (+0.0%) | 1.2K -818.0 (-41.4%) | 0.01% -0.007 pp | 0.00% +0.000 pp | USD3.77 -79.3% | 5 qtrs — |
| 25 | QUENT CAPITAL, LLC | 925.00 +817.0 (+756.5%) | 719.00 +585.0 (+436.6%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD0.83 -6.0% | 5 qtrs — |
| 26 | CITIGROUP INC | 843.00 -774.0 (-47.9%) | 655.00 -1.4K (-67.3%) | 0.01% -0.007 pp | 0.00% +0.000 pp | USD1.24 -37.1% | 2 qtrs — |
| 27 | LUMINIST CAPITAL LLC | 435.00 +— (+0.0%) | 338.00 -258.0 (-43.3%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD3.45 -77.4% | 5 qtrs — |
| 28 | NEWEDGE ADVISORS, LLC | 400.00 -25.0K (-98.4%) | 311.00 -31.2K (-99.0%) | 0.00% -0.229 pp | 0.00% 0.000 pp | USD1.58 -50.6% | 3 qtrs — |
| 29 | BANK OF AMERICA CORP /DE/ | 307.00 -115.0 (-27.3%) | 238.00 -285.0 (-54.5%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD1.86 -58.1% | 5 qtrs — |
| 30 | MURPHY & MULLICK CAPITAL MANAGEMENT CORP | 160.00 +— (+0.0%) | 124.00 -127.0 (-50.6%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD4.00 -80.5% | 5 qtrs — |
| 31 | PRINCETON GLOBAL ASSET MANAGEMENT LLC | 160.00 +— (+0.0%) | 124.00 -74.0 (-37.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.00 -80.5% | 5 qtrs — |
| 32 | JPMORGAN CHASE & CO | 120.00 +— (+0.0%) | 93.00 -56.0 (-37.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.77 -79.3% | 5 qtrs — |
| 33 | SMALLWOOD WEALTH INVESTMENT MANAGEMENT, LLC | 120.00 +— (+0.0%) | 93.00 -55.0 (-37.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.48 -47.3% | 4 qtrs — |
| 34 | BNP PARIBAS ARBITRAGE, SNC | 107.00 +— (+0.0%) | 83.00 -50.0 (-37.6%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD4.00 -80.5% | 5 qtrs — |
| 35 | SRS CAPITAL ADVISORS, INC. | 84.00 +— (+0.0%) | 65.00 -39.0 (-37.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.24 -37.1% | 2 qtrs — |
| 36 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 80.00 +— (+0.0%) | 61.00 -38.0 (-38.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.49 -47.7% | 4 qtrs — |
| 37 | HARBOUR INVESTMENTS, INC. | 50.00 +50.0 (+100.0%) | 39.00 +39.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD0.76 +2.6% | 1 qtrs NEW |
| 38 | FAIRSCALE CAPITAL, LLC | 42.00 +— (+0.0%) | 33.00 -19.0 (-36.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD4.00 -80.5% | 5 qtrs — |
| 39 | WELLS FARGO & COMPANY/MN | 40.00 +— (+0.0%) | 31.00 -19.0 (-38.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.23 -36.6% | 2 qtrs — |
| 40 | TD WATERHOUSE CANADA INC. | 4.00 +4.0 (+100.0%) | 3.00 +3.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.75 +4.0% | 1 qtrs NEW |
| 41 | LEGACY WEALTH MANAGMENT, LLC/ID | — -930.0 (-100.0%) | — -1.2K (-100.0%) | 0.00% -0.008 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 42 | FARTHER FINANCE ADVISORS, LLC | — -343.0 (-100.0%) | — -425.0 (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 43 | SIMPLEX TRADING, LLC | — -9.6K (-100.0%) | — -11.0K (-100.0%) | 0.00% -0.087 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 44 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | — -10.0K (-100.0%) | — -12.0K (-100.0%) | 0.00% -0.091 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 107.4K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
1.00
Neutral
Buys
4
Sells
4
Shares acquired
6.71M
Shares disposed
6.71M
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-08 | Mazur Leonard L | Director / Officer | A-Award | A | Warrant to Purchase Common Stock | 125,490 | 28.75 | 3.61M | 125,490 | D | ↗ |
| 2025-08-08 | HOLUBIAK MYRON Z | Director / Officer | A-Award | A | Warrant to Purchase Common Stock | 31,373 | 28.75 | 902.0K | 31,373 | D | ↗ |
| 2024-11-07 | Webb Carol | Director | A-Award | A | Stock Option (Right to Purchase Common Stock) | 125,000 | 0.38 | 47.5K | 125,000 | D | ↗ |
| 2024-11-07 | Smith Robert Joseph | Director | A-Award | A | Stock Option (Right to Purchase Common Stock) | 125,000 | 0.38 | 47.5K | 125,000 | D | ↗ |
| 2024-11-07 | Mazur Leonard L | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Purchase Common Stock) | 600,000 | 0.38 | 228.0K | 600,000 | D | ↗ |
| 2024-11-07 | MCGRATH DENNIS M | Director | A-Award | A | Stock Option (Right to Purchase Common Stock) | 125,000 | 0.38 | 47.5K | 125,000 | D | ↗ |
| 2024-11-07 | Holuka Eugene Myron | Director | A-Award | A | Stock Option (Right to Purchase Common Stock) | 125,000 | 0.38 | 47.5K | 125,000 | D | ↗ |
| 2024-11-07 | HOLUBIAK MYRON Z | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.38 | 28.5K | 75,000 | I | ↗ |
| 2024-11-07 | Dutia Suren G | Director | A-Award | A | Stock Option (Right to Purchase Common Stock) | 125,000 | 0.38 | 47.5K | 125,000 | D | ↗ |
| 2024-11-07 | Czuczman Myron | Officer | A-Award | A | Stock Option (Right to Purchase Common Stock) | 300,000 | 0.38 | 114.0K | 300,000 | D | ↗ |
| 2024-11-07 | Bartushak Jaime | Officer | A-Award | A | Stock Option (Right to Purchase Common Stock) | 350,000 | 0.38 | 133.0K | 350,000 | D | ↗ |
| 2024-09-25 | Mazur Leonard L | Director / Officer / 10% Owner | A-Award | A | Warrant to Purchase Common Stock | 2,234,700 | 0.77 | 1.72M | 2,234,700 | D | ↗ |
| 2024-09-25 | HOLUBIAK MYRON Z | Director / Officer | D-Return | D | Warrant to Purchase Common Stock | 558,597 | 0.77 | 430.1K | 0 | D | ↗ |
| 2024-08-14 | Mazur Leonard L | Director / Officer / 10% Owner | A-Award | A | Warrant to Purchase Common Stock | 3,137,255 | 1.15 | 3.61M | 3,137,255 | D | ↗ |
| 2024-08-14 | HOLUBIAK MYRON Z | Director / Officer | A-Award | A | Warrant to Purchase Common Stock | 784,314 | 1.15 | 902.0K | 784,314 | D | ↗ |
| 2024-04-03 | Mazur Leonard L | Director / Officer / 10% Owner | A-Award | A | Warrant to Purchase Common Stock | 1,165,048 | 1.42 | 1.65M | 1,165,048 | — | ↗ |
| 2024-04-03 | HOLUBIAK MYRON Z | Director / Officer | A-Award | A | Warrant to Purchase Common Stock | 129,450 | 1.42 | 183.8K | 129,450 | — | ↗ |
| 2024-03-14 | Smith Robert Joseph | Director | A-Award | A | Stock Option (Right to Purchase Common Stock) | 75,000 | 0.69 | 51.8K | 75,000 | — | ↗ |
| 2024-03-13 | Holuka Eugene Myron | Director | M-Exempt | A | Common Stock | 2,415 | 0.02 | 36.23 | 2,415 | — | ↗ |
| 2024-03-12 | Smith Robert Joseph | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-04 | Webb Carol | Director | F-InKind | D | Common Stock | 236 | 0.77 | 180.78 | 11,835 | — | ↗ |
| 2023-10-10 | Webb Carol | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 0.70 | 52.5K | 75,000 | — | ↗ |
| 2023-10-10 | Mazur Leonard L | Director / Officer / 10% Owner | A-Award | A | Option to Purchase Common Stock | 550,000 | 0.70 | 385.0K | 550,000 | — | ↗ |
| 2023-10-10 | MCGRATH DENNIS M | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 0.70 | 52.5K | 75,000 | — | ↗ |
| 2023-10-10 | Holuka Eugene Myron | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 0.70 | 52.5K | 75,000 | — | ↗ |
| 2023-10-10 | HOLUBIAK MYRON Z | Director / Officer | A-Award | A | Options to Purchase Common Stock | 400,000 | 0.70 | 280.0K | 400,000 | — | ↗ |
| 2023-10-10 | Dutia Suren G | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 0.70 | 52.5K | 75,000 | — | ↗ |
| 2023-10-10 | Czuczman Myron | Officer | A-Award | A | Stock Option (Right to Purchase Common Stock) | 300,000 | 0.70 | 210.0K | 300,000 | — | ↗ |
| 2023-10-10 | Bartushak Jaime | Officer | A-Award | A | Stock Option (Right to Purchase Common Stock) | 300,000 | 0.70 | 210.0K | 300,000 | — | ↗ |
| 2023-02-07 | MCGRATH DENNIS M | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 1.42 | 106.5K | 75,000 | — | ↗ |
| 2022-10-04 | Webb Carol | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2022-10-04 | SAFIR HOWARD | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2022-10-04 | Mazur Leonard L | Officer | A-Award | A | Option to Purchase Common Stock | 550,000 | 0.00 | — | 550,000 | — | ↗ |
| 2022-10-04 | Kane William | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2022-10-04 | Holuka Eugene Myron | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2022-10-04 | HOLUBIAK MYRON Z | Officer | A-Award | A | Options to Purchase Common Stock | 400,000 | 0.00 | — | 400,000 | — | ↗ |
| 2022-10-04 | Dutia Suren G | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2022-10-04 | Czuczman Myron | Officer | A-Award | A | Stock Option (Right to Purchase Common Stock) | 300,000 | 0.00 | — | 300,000 | — | ↗ |
| 2022-10-04 | Bartushak Jaime | Officer | A-Award | A | Stock Option (Right to Purchase Common Stock) | 300,000 | 0.00 | — | 300,000 | — | ↗ |
| 2021-10-11 | Webb Carol | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 2.04 | 153.0K | 75,000 | — | ↗ |
| 2021-10-11 | SAFIR HOWARD | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 2.04 | 153.0K | 75,000 | — | ↗ |
| 2021-10-11 | Mazur Leonard L | Director / Officer / 10% Owner | A-Award | A | Option to Purchase Common Stock | 650,000 | 2.04 | 1.33M | 650,000 | — | ↗ |
| 2021-10-11 | Kane William | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 2.04 | 153.0K | 75,000 | — | ↗ |
| 2021-10-11 | Holuka Eugene Myron | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 2.04 | 153.0K | 75,000 | — | ↗ |
| 2021-10-11 | HOLUBIAK MYRON Z | Director / Officer | A-Award | A | Options to Purchase Common Stock | 15,000 | 2.04 | 30.6K | 15,000 | — | ↗ |
| 2021-10-11 | Dutia Suren G | Director | A-Award | A | Options to Purchase Common Stock | 75,000 | 2.04 | 153.0K | 75,000 | — | ↗ |
| 2021-10-11 | Czuczman Myron | Officer | A-Award | A | Stock Option (Right to Purchase Common Stock) | 300,000 | 2.04 | 612.0K | 300,000 | — | ↗ |
| 2021-10-11 | Bartushak Jaime | Officer | A-Award | A | Stock Option (Right to Purchase Common Stock) | 300,000 | 2.04 | 612.0K | 300,000 | — | ↗ |
| 2021-07-22 | Webb Carol | Director | A-Award | A | Options to Purchase Common Stock | 15,000 | 2.00 | 30.0K | 15,000 | — | ↗ |
| 2021-07-22 | SAFIR HOWARD | Director | A-Award | A | Options to Purchase Common Stock | 15,000 | 2.00 | 30.0K | 15,000 | — | ↗ |
| 2021-07-22 | Mazur Leonard L | Director / Officer / 10% Owner | A-Award | A | Options to Purchase Common Stock | 300,000 | 2.00 | 600.0K | 300,000 | — | ↗ |
| 2021-07-22 | Kane William | Director | A-Award | A | Options to Purchase Common Stock | 15,000 | 2.00 | 30.0K | 15,000 | — | ↗ |
| 2021-07-22 | Holuka Eugene Myron | Director | A-Award | A | Options to Purchase Common Stock | 15,000 | 2.00 | 30.0K | 15,000 | — | ↗ |
| 2021-07-22 | HOLUBIAK MYRON Z | Director / Officer / 10% Owner | A-Award | A | Options to Purchase Common Stock | 300,000 | 2.00 | 600.0K | 300,000 | — | ↗ |
| 2021-07-22 | Dutia Suren G | Director | A-Award | A | Options to Purchase Common Stock | 15,000 | 2.00 | 30.0K | 15,000 | — | ↗ |
| 2021-07-22 | Bartushak Jaime | Officer | A-Award | A | Stock Option (Right to Purchase Common Stock) | 100,000 | 2.00 | 200.0K | 100,000 | — | ↗ |
| 2021-02-16 | Webb Carol | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 1.69 | 42.3K | 25,000 | — | ↗ |
| 2021-02-16 | SAFIR HOWARD | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 1.69 | 42.3K | 25,000 | — | ↗ |
| 2021-02-16 | Kane William | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 1.69 | 42.3K | 25,000 | — | ↗ |
| 2021-02-16 | Holuka Eugene Myron | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 1.69 | 42.3K | 25,000 | — | ↗ |
| 2021-02-16 | Dutia Suren G | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 1.69 | 42.3K | 25,000 | — | ↗ |
| 2020-10-06 | Webb Carol | Director | A-Award | A | Options to Purchase Common Stock | 35,000 | 1.01 | 35.4K | 35,000 | — | ↗ |
| 2020-10-06 | SAFIR HOWARD | Director | A-Award | A | Options to Purchase Common Stock | 35,000 | 1.01 | 35.4K | 35,000 | — | ↗ |
| 2020-10-06 | Mazur Leonard L | Director / Officer / 10% Owner | A-Award | A | Options to Purchase Common Stock | 200,000 | 1.01 | 202.0K | 200,000 | — | ↗ |
| 2020-10-06 | Kane William | Director | A-Award | A | Options to Purchase Common Stock | 35,000 | 1.01 | 35.4K | 35,000 | — | ↗ |
| 2020-10-06 | Holuka Eugene Myron | Director | A-Award | A | Options to Purchase Common Stock | 35,000 | 1.01 | 35.4K | 35,000 | — | ↗ |
| 2020-10-06 | HOLUBIAK MYRON Z | Director / Officer / 10% Owner | A-Award | A | Options to Purchase Common Stock | 200,000 | 1.01 | 202.0K | 200,000 | — | ↗ |
| 2020-10-06 | Dutia Suren G | Director | A-Award | A | Options to Purchase Common Stock | 35,000 | 1.01 | 35.4K | 35,000 | — | ↗ |
| 2020-10-06 | Bartushak Jaime | Officer | A-Award | A | Stock Option (Right to Purchase Common Stock) | 125,000 | 1.01 | 126.3K | 125,000 | — | ↗ |
| 2020-07-14 | Czuczman Myron | Officer | A-Award | A | Stock Option (Right to Purchase Common Stock) ) | 500,000 | 1.19 | 595.0K | 500,000 | — | ↗ |
| 2020-07-07 | Webb Carol | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 1.39 | 34.8K | 25,000 | — | ↗ |
| 2020-07-07 | SAFIR HOWARD | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 1.39 | 34.8K | 25,000 | — | ↗ |
| 2020-07-07 | Kane William | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 1.39 | 34.8K | 25,000 | — | ↗ |
| 2020-07-07 | Holuka Eugene Myron | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 1.39 | 34.8K | 25,000 | — | ↗ |
| 2020-07-07 | Dutia Suren G | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 1.39 | 34.8K | 25,000 | — | ↗ |
| 2019-10-08 | Webb Carol | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 0.67 | 16.8K | 25,000 | — | ↗ |
| 2019-10-08 | SAFIR HOWARD | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 0.67 | 16.8K | 25,000 | — | ↗ |
| 2019-10-08 | Mazur Leonard L | Director / Officer / 10% Owner | A-Award | A | Options to Purchase Common Stock | 175,000 | 0.67 | 117.3K | 175,000 | — | ↗ |
| 2019-10-08 | Kane William | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 0.67 | 16.8K | 25,000 | — | ↗ |
| 2019-10-08 | Holuka Eugene Myron | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 0.67 | 16.8K | 25,000 | — | ↗ |
| 2019-10-08 | HOLUBIAK MYRON Z | Director / Officer / 10% Owner | A-Award | A | Options to Purchase Common Stock | 175,000 | 0.67 | 117.3K | 175,000 | — | ↗ |
| 2019-10-08 | Dutia Suren G | Director | A-Award | A | Options to Purchase Common Stock | 25,000 | 0.67 | 16.8K | 25,000 | — | ↗ |
| 2019-10-08 | Bartushak Jaime | Officer | A-Award | A | Stock Option (Right to Purchase Common Stock) | 100,000 | 0.67 | 67.0K | 100,000 | — | ↗ |
| 2019-09-27 | Mazur Leonard L | Director / Officer / 10% Owner | P-Purchase | A | Warrant to Purchase Common Stock | 2,234,700 | 0.77 | 1.72M | 2,234,700 | — | ↗ |
| 2019-09-27 | HOLUBIAK MYRON Z | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 558,597 | 0.90 | 500.0K | 1,992,243 | — | ↗ |
| 2019-04-03 | Mazur Leonard L | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,165,048 | 1.55 | 1.80M | 8,020,643 | — | ↗ |
| 2019-04-03 | HOLUBIAK MYRON Z | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 129,450 | 1.55 | 200.0K | 1,433,646 | — | ↗ |
| 2018-09-04 | Webb Carol | Director | A-Award | A | Options to Purchase Common Stock | 15,000 | 1.62 | 24.3K | 15,000 | — | ↗ |
| 2018-09-04 | SAFIR HOWARD | Director | A-Award | A | Options to Purchase Common Stock | 15,000 | 1.62 | 24.3K | 15,000 | — | ↗ |
| 2018-09-04 | Mazur Leonard L | Director / Officer / 10% Owner | A-Award | A | Options to Purchase Common Stock | 150,000 | 1.62 | 243.0K | 150,000 | — | ↗ |
| 2018-09-04 | Kane William | Director | A-Award | A | Options to Purchase Common Stock | 15,000 | 1.62 | 24.3K | 15,000 | — | ↗ |
| 2018-09-04 | Holuka Eugene Myron | Director | A-Award | A | Options to Purchase Common Stock | 15,000 | 1.62 | 24.3K | 15,000 | — | ↗ |
| 2018-09-04 | HOLUBIAK MYRON Z | Director / Officer / 10% Owner | A-Award | A | Options to Purchase Common Stock | 150,000 | 1.62 | 243.0K | 150,000 | — | ↗ |
| 2018-09-04 | Dutia Suren G | Director | A-Award | A | Options to Purchase Common Stock | 15,000 | 1.62 | 24.3K | 15,000 | — | ↗ |
| 2018-09-04 | Bartushak Jaime | Officer | A-Award | A | Stock Option (Right to Purchase Common Stock) | 70,000 | 1.62 | 113.4K | 70,000 | — | ↗ |
| 2018-08-13 | Mazur Leonard L | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 3,137,255 | 1.28 | 4.00M | 6,855,595 | — | ↗ |
| 2018-08-13 | HOLUBIAK MYRON Z | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 784,314 | 1.28 | 1.00M | 1,304,196 | — | ↗ |
| 2018-03-29 | Mazur Leonard L | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 167,504 | 2.99 | 500.0K | 3,718,340 | — | ↗ |
| 2018-03-28 | HOLUBIAK MYRON Z | Director / Officer | P-Purchase | A | Common Stock | 2,915 | 3.09 | 9.0K | 519,882 | — | ↗ |
| 2017-12-19 | Mazur Leonard L | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 213,106 | 4.69 | 999.5K | 3,550,836 | — | ↗ |
| 2017-11-27 | Bartushak Jaime | Officer | — | D | Common Stock | 0 | 0.00 | — | 60,353 | — | ↗ |
| 2017-09-15 | Webb Carol | Director | A-Award | A | Options to Purchase Common Stock | 10,000 | 3.45 | 34.5K | 10,000 | — | ↗ |
| 2017-09-15 | SAFIR HOWARD | Director | A-Award | A | Options to Purchase Common Stock | 10,000 | 3.45 | 34.5K | 10,000 | — | ↗ |
| 2017-09-15 | Mazur Leonard L | Director / Officer / 10% Owner | A-Award | A | Options to Purchase Common Stock | 40,000 | 3.45 | 138.0K | 40,000 | — | ↗ |
| 2017-09-15 | Kane William | Director | A-Award | A | Options to Purchase Common Stock | 10,000 | 3.45 | 34.5K | 10,000 | — | ↗ |
| 2017-09-15 | Holuka Eugene Myron | Director | A-Award | A | Options to Purchase Common Stock | 10,000 | 3.45 | 34.5K | 10,000 | — | ↗ |
| 2017-09-15 | HOLUBIAK MYRON Z | Director / Officer | A-Award | A | Options to Purchase Common Stock | 40,000 | 3.45 | 138.0K | 40,000 | — | ↗ |
| 2017-09-15 | Dutia Suren G | Director | A-Award | A | Options to Purchase Common Stock | 10,000 | 3.45 | 34.5K | 10,000 | — | ↗ |
| 2017-08-24 | Mazur Leonard L | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 11,000 | 2.68 | 29.5K | 3,337,730 | — | ↗ |
| 2017-08-08 | Mazur Leonard L | Director / Officer / 10% Owner | C-Conversion | A | Common Stock | 1,547,067 | 3.09 | 4.78M | 3,326,730 | — | ↗ |
| 2016-06-23 | Webb Carol | Director | A-Award | A | Options to Purchase Common Stock | 200,000 | 0.80 | 160.0K | 200,000 | — | ↗ |
| 2016-06-23 | SAFIR HOWARD | Director | A-Award | A | Options to Purchase Common Stock | 200,000 | 0.80 | 160.0K | 200,000 | — | ↗ |
| 2016-06-23 | Kane William | Director | A-Award | A | Options to Purchase Common Stock | 200,000 | 0.80 | 160.0K | 200,000 | — | ↗ |
| 2016-06-23 | Holuka Eugene Myron | Director | — | D | Options to Purchase Common Stock | 36,212 | 0.00 | 36.21 | 0 | — | ↗ |
| 2016-03-30 | Webb Carol | Director | — | D | Options to Purchase Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-03-30 | SAFIR HOWARD | Director | — | D | Options to Purchase Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-03-30 | Mazur Leonard L | Director | J-Other | A | Warrant to Purchase Common Stock | 0 | 0.50 | — | 4,866,420 | — | ↗ |
| 2016-03-30 | Kane William | Director | — | D | Options to Purchase Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-03-30 | HOLUBIAK MYRON Z | Director / Officer | J-Other | A | Warrant to Purchase Common Stock | 0 | 0.00 | — | 694,217 | — | ↗ |
| 2015-10-08 | Dutia Suren G | Director | — | D | Options to Purchase Common Stock | 400,000 | 0.54 | 216.0K | 0 | — | ↗ |
| 2015-10-01 | HOLUBIAK MYRON Z | Director | — | D | Options to Purchase Common Stock | 400,000 | 0.54 | 216.0K | 0 | — | ↗ |
| 2014-09-12 | Mazur Leonard L | Director | — | D | Options to Purchase Common Stock | 1,500,000 | 0.45 | 675.0K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
11.17M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Leonard L. Mazur | Co-Founder, Chief Executive Officer, Chairman & Secretary | 712.5K | male |
| Myron Z. Holubiak | Co-Founder & Executive Vice Chairman | 675.0K | male |
| Myron S. Czuczman | Executive Vice President & Chief Medical Officer | 607.5K | — |
| Jaime Bartushak | Chief Business Officer & Chief Financial Officer | 589.0K | male |
| Kelly Creighton | Executive Vice President of Chemistry, Manufacturing & Controls | — | male |
| Alan Lader | Senior Vice President & Head of Clinical Operations and Quality Assurance | — | — |
| Nikolas Burlew | Executive Vice President of Quality Assurance | — | male |
| Dhananjay G. Wadekar | Senior Vice President of Business Strategy | — | male |
| Gary F. Talarico | Executive Vice President of Operations | — | male |
| Ilanit Allen | Vice President of Investor Relations & Corporation Communications | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CTXR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
